利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.028 秒)

    Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
    12.
    发明申请
    Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer 审中-公开
    用于治疗和预防癌症的杂交细胞疫苗的方法和组合物

    公开(公告)号：US20050238627A1

    公开(公告)日：2005-10-27

    申请号：US11071862

    申请日：2005-03-02

    申请人： Tsuneya Ohno ,  Donald Kufe

    发明人： Tsuneya Ohno ,  Donald Kufe

    IPC分类号： A01N63/00 ,  A01N65/00 ,  A61K39/00 ,  A61K48/00 ,  C12N5/00 ,  C12N5/16

    CPC分类号： C12N5/16 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/55538

    摘要： The present invention relates to methods for treating and preventing cancer and for treating precancerous lesions by administering a therapeutically effective dose of a vaccine comprising fusion cells formed by fusion of antigen presenting cells and non-dendritic cells that contain genomic DNA or cDNA derived from a tumor cell or a pre-cancerous cell to a cancer patient or patient with a precancerous lesion. In certain embodiments, such vaccines are administered in combination with a cytokine or other molecule that stimulates a cytotoxic T cell (CTL) response and/or a humoral immune response. The present invention also relates to methods for treating and preventing an infectious disease by administering a therapeutically effective dose of a vaccine comprising fusion cells formed by fusion of antigen presenting cells and non-dendritic cells that contain genomic DNA or cDNA derived from the infectious agent that causes the infectious disease to be treated or prevented to a subject. The present invention also related to methods for producing the fusion cells to be used with the methods of the invention. The present invention also provides compositions comprising the fusion cells to be used with the methods of the invention.

    摘要翻译： 本发明涉及治疗和预防癌症和治疗癌前病变的方法，其通过施用治疗有效剂量的疫苗，其包含通过抗原呈递细胞融合形成的融合细胞和含有源自肿瘤的基因组DNA或cDNA的非树突状细胞 细胞或癌前细胞转移至患有癌前病变的癌症患者或患者。 在某些实施方案中，这样的疫苗与细胞因子或刺激细胞毒性T细胞（CTL）应答和/或体液免疫应答的其它分子组合施用。 本发明还涉及通过施用治疗有效剂量的疫苗，其包含由抗原呈递细胞融合形成的融合细胞和含有衍生自感染因子的基因组DNA或cDNA的非树突状细胞的治疗和预防感染性疾病的方法， 导致感染性疾病被治疗或预防对象。 本发明还涉及用于生产与本发明的方法一起使用的融合细胞的方法。 本发明还提供了包含与本发明方法一起使用的融合细胞的组合物。

    DNA damaging agents in combination with tyrosine kinase inhibitors
    14.
    发明授权
    DNA damaging agents in combination with tyrosine kinase inhibitors 有权
    DNA损伤剂与酪氨酸激酶抑制剂组合

    公开(公告)号：US07838512B2

    公开(公告)日：2010-11-23

    申请号：US11381311

    申请日：2006-05-02

    申请人： Donald Kufe ,  Ralph R. Weichselbaum

    发明人： Donald Kufe ,  Ralph R. Weichselbaum

    IPC分类号： A61K31/66

    CPC分类号： A61N5/10 ,  A61K31/365 ,  A61K31/40 ,  A61K31/70 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7072 ,  A61K41/0019 ,  A61K41/0023 ,  A61K31/35 ,  A61K2300/00 ,  A61K31/495 ,  A61K31/41 ,  A61K31/38

    摘要： Methods and compositions for enhancing cancer cell death using therapeutically effective amounts of DNA damaging agent(s) that act in combination to enhance cancer cell death, e.g., nucleic acid precursors, and protein tyrosine kinase inhibitors, e.g., that inhibit EGFR activity. The agents and inhibitors are administered in an amount effective to kill cancer cells, that is, the combined effect is sufficient so that cancer cell death is enhanced. If not administered at the same time, the DNA damaging agent(s) and tyrosine kinase inhibitors are administered close enough in time so they are still able to enhance cancer cell death. The methods and compositions are useful to treat neoplastic disease, e.g., pancreatic cancer.

    摘要翻译： 使用联合作用以增强癌细胞死亡的治疗有效量的DNA损伤剂（例如，核酸前体）和蛋白酪氨酸激酶抑制剂（例如抑制EGFR活性）来增强癌细胞死亡的方法和组合物。 以有效杀死癌细胞的量施用药剂和抑制剂，即组合效果足以使癌细胞死亡增强。 如果不同时施用，DNA损伤剂和酪氨酸激酶抑制剂在时间上足够接近地施用，因此它们仍然能够增强癌细胞死亡。 所述方法和组合物可用于治疗肿瘤性疾病，例如胰腺癌。